Information
2025.03.24　
サイトを公開しました。

文献のご紹介　※セラヨコ・トーク付き

(68Ga|Ga-PSMA-11 PET Tumor Volume Predicts Overall Survival of Patients with Metastatic Prostate Cancer Undergoing Taxane-Based Chemotherapy

DOI: 10.2967/
jnumed. 125.269584

Resisting RECIST: PSMA PET and Regulatory Change in Prostate Cancer

DOI: 10.2967/
jnumed.125.271144

First-in-human results of terbium-161 [16ªTb]Tb-PSMA-I&T dual beta-Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET):a single-centre, single-arm, phase 1/2 study

DOI: 10.1016/
S1470-2045(25)00332-8

Prognostic and predictive value of baseline PSMA-PETtotal tumour volume and SUVmean in metastatic castrationresistant prostate cancer in ENZA-p (ANZUP1901): a substudyfrom a multicentre, open-label, randomised, phase 2 trial

DOI: 10.1016/
S1470-2045(25)00339-0

The Use of PSMA PET/CT Improves Overall Survival in Men with Biochemically Recurrent Prostate Cancer Treated with Salvage Radiotherapy: Real-World Data from anEntire Country

DOI: 10.2967/
jnumed.125.269996

Evidence-Based Clinical Protocols to Monitor Efficacy of [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data

DOI: 10.2967/
jnumed.124.269431

Treatment Response Evaluation in Prostate Cancer Using PSMA PET/CT

DOI: 10.2967/
jnumed.124.268071

First-in-human results of terbium-161[161Tb]Tb-PSMA-I&T radioligand treatment in patients with metastatic castration-resistant prostate cancer (VIOLET): A single-centre, single-arm, phase I/ll study.

Journal of Clinical Oncology • Volume 43, Number 16 suppl
DOI　10.1200/
JCO.2025.43.16_suppl.5010

1 2 3 次へ »

※セラヨコ・トーク＝抄読会でのセラヨコメンバーのつぶやき

動画コンテンツ